# US 10,864,188 B2 · Anti-microbial composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,188 B2
- Document ID: US10864188B2
- Status: Granted
- Kind: B2
- Application number: 15/269,364
- Filed: 2016-09-19
- Published: 2017-01-05
- Granted: 2020-12-15
- Earliest claimed: 2010-12-09
- Assignees: Septeos
- Applicants: Septeos
- Inventors: Nicolas Tesse
- Web page: https://patentgrep.com/patent/US10864188B2

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A01N 35/02: containing aliphatically bound aldehyde or keto groups, or thio analogues thereof; Derivatives thereof, e.g. acetals
- A01N 65/24: Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/015: carbocyclic
- A61K 31/04: Nitro compounds
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/08: acyclic, e.g. paraformaldehyde
- A61K 31/11: Aldehydes
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/222: with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 31/35: having six-membered rings with one oxygen as the only ring hetero atom
- A61K 31/37: Coumarins, e.g. psoralen
- A61K 36/54: Lauraceae (Laurel family), e.g. cinnamon or sassafras
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention pertains to an anti-microbial, in particular anti-bacterial and/or anti-fungal composition comprising cinnamaldehyde, trans-2-methoxycinnamaldehyde, cinnamyl acetate and linalool. In particular this composition is intended for preventing and/or treating microbial infection in an animal.

## Claims

### Claim 1

A method for antimicrobial treatment, said method comprising:
administering to a patient in need thereof a synthetic composition comprising:
an active blend comprising:
trans-cinnamaldehyde, trans-2-methoxycinnamaldehyde, cinnamyl acetate, and linalool,
optionally cineole, beta-caryophyllene, and/or benzyl benzoate,
wherein the number of compounds in the active blend is equal to or lower than seven,
optionally a drug,
wherein the composition is free of coumarin,
wherein the total amount of safrole is below 1% by weight compared to the total weight of the composition,
wherein the composition comprises at least one pharmaceutical acceptable excipient, and
wherein the infection to be treated is a digestive system infection and results from bacteria.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the bacteria are drug-resistant bacteria.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the bacteria involved in the infection are Gram-negative bacteria.

### Claim 4 (depends on 1)

The method according to claim 1 for treating peptic ulcer.

### Claim 5

A method for antimicrobial treatment, said method comprising:
administering to a patient in need thereof a synthetic composition comprising:
an active blend including:
trans-cinnamaldehyde, trans-2-methoxycinnamaldehyde, cinnamyl acetate, and linalool,
at least cineole, and/or benzyl benzoate,
optionally beta-caryophyllene,
wherein the number of compounds in the active blend is equal to or lower than seven,
optionally a drug,
wherein the composition is free of coumarin and safrole,
wherein the synthetic composition comprises at least one pharmaceutical acceptable excipient, and
wherein the infection to be treated is a digestive system infection and results from bacteria.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the bacteria are drug-resistant bacteria.